KRAS mutations predominantly occur at critical amino acid residues (G12, G13, Q61, and A146) and are frequently implicated in various hematologic malignancies, including acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), juvenile myelomonocytic leukemia (JMML), and AML (23). This evidence concerns the gene KRAS and myelodysplastic syndrome.